Gut flora in gastrointestinal disease

European Journal of Surgery, Supplement

Volumn 168, Issue 587, 2002, Pages 47-52

  Shanahan, Fergus ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL FLORA; CLOSTRIDIUM DIFFICILE; CONFERENCE PAPER; CROHN DISEASE; ENTERITIS; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; GENETIC SUSCEPTIBILITY; HUMAN; INTESTINE FLORA; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES BOULARDII; SALMONELLA TYPHIMURIUM; ULCERATIVE COLITIS; ADAPTATION; IMMUNOLOGY; INTESTINE; INTESTINE MUCOSA; MICROBIOLOGY; PATHOPHYSIOLOGY; REVIEW; T LYMPHOCYTE;

ADAPTATION, PHYSIOLOGICAL; COLITIS, ULCERATIVE; CROHN DISEASE; GASTROINTESTINAL DISEASES; HUMANS; INTESTINAL MUCOSA; INTESTINES; T-LYMPHOCYTES;

EID: 0036960764     PISSN: 1102416X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol 1996; 4: 430-435.
2. Berg RD. Probiotics, prebiotics or 'conbiotics'? Trends Microbiol 1998; 6: 89-92.
3. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 1999; 11: 648-656.
4. Bocci V. The neglected organ: bacterial flora has a crucial immunostimulatory role. Perspect Biol Med 1992; 35: 251-260.
5. Bry L, Falk PG, Midtvedt T, Gordon JI. A model system of host-microbial interactions in an open mammalian ecosystem. Science 1996; 273: 1380-1383.
6. Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative. Gastroenterology 1998; 116: 1246-1260.
7. Cario E, Rosenberg IM, Brandwein SL, Beck PL, Reinecker H-C, Podolsky DK. Lipopolysaccharide activates distinct signalling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J Immunol 2000; 164: 966-972.
8. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68: 7010-7017.
9. Collins JK, Murphy L, O'Mahony L, Dunne C, O'Sullivan GC, Shanahan F. A. Controlled trial of probiotic treatment of IL-10 knockout mice. Gastroenterology 1999; 116: G2981.
10. + T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 1998; 187: 855-864.
11. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998; 115: 1405-1413.
12. De Winter H, Cheroutre H, Kronenberg M. The yin and yang of T cells in intestinal inflammation: pathogenic and protective roles in a mouse colitis model. Am J Physiol Gastrointest Liver Physiol 1999; 276: G1317-G1321.
13. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262-267.
14. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Büschenfelde K-H. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102: 448-455.
15. Duchmann R, Schmitt E, Knolle P, Meyer zum Büschenfelde K-H, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996; 26: 934-938.
16. Duchmann R, May E, Heike M, Knolle P, Neurath M, Meyer zum Büschenfelde K-H. T cell specificity and cross reactivity toward enterobacteria, Bacteroides, Bifidobacterium, and antigens from resident intestinal flora in humans. Gut 1999; 44: 812-818.
17. Dugas B, Mercenier A, Lenoir-Wijnkoop I, Arnaud C, Dugas N, Postaire E. Immunity and probiotics. Immunol Today 1999; 20: 387-390.
18. Elson Co, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109: 1344-1367.
19. Faria AM, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol 1999; 73: 153-264.
20. Feagan B. Antibiotics are not effective therapy for Crohn's disease (time to remove the rose-coloured glasses). Inflamm Bowel Dis 1997; 3: 314-317.
21. Fuss IJ, Strober W. Animal models of inflammatory bowel disease: insights into the immunopathogenesis of Crohn's disease and ulcerative colitis. Current Opinion in Gastroenterology 1998; 14: 476-482.
22. Gewirtz AT, Madara JL. Periscope, up! Monitoring microbes in the intestine. Nat Immun 2001; 2: 288-290.
23. Gionchietti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-309.
24. Gordon JI, Hooper LV, McNevin SM, Wong M, Bry L. Epithelial cell growth and differentiation III. Promoting diversity in the intestine: conversations between the microflora, epithelium, and diffuse GALT. Am J Physiol Gastrointest Liver Physiol 1997; 273: G565-G570.
25. Harper PH, Lee ECG, Kettlewell MGW, Bennett MK, Jewell DP. Role of the faecal stream in the maintenance of Crohn's colitis. Gut 1985; 26: 279-284.
26. Iwasaki A, Kelsall BL. Freshly isolated Peyer's patch but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J Exp Med 1999; 190: 229-239.
27. Janowitz HD, Croen EC, Sachet DB. The role of the fecal stream in Crohn's disease: a historical and analytical review. Inflamm Bowel Dis 1998; 4: 29-39.
28. Kagnoff MF, Eckmann L. Epithelial cells as sensors for microbial infection. J Clin Invest 1997; 100: 6-10.
29. Kronenberg M, Cheroutre H. Do mucosal T cells prevent intestinal inflammation? Gastroenterology 2000; 118: 974-977.
30. Kruis W, Schütz E, Fric P, Fixa B, Judmaiers G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-858.
31. Kulberg MC, Ward MJ, Gorelick PL, et al. Helicobacter hepaticus triggers colitis in specific pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma-interferon-dependent mechanism. Infect Immun 1998; 66: 5157-5166.
32. Mackowiak PA. The normal microbial flora. N Engl J Med 1982: 307: 83-93.
33. MacPherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996; 38: 365-375.
34. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116: 1107-1114.
35. Midtvedt T. Microbial functional activities. In: Hanson LA, Yolken RH, (eds. Intestinal microflora, Nestle Nutrition Workshop Series. Philadelphia: Lippincott-Raven, 1999; 42: 79-96.
36. Neutra MR. Role of M cells in transepithelial transport of antigens and pathogens to the mucosal immune system. Am J Physiol Gastrointest Liver Physio. 1998; 274: G785-G791.
37. O'Mahony L, Feeney NM, O'Halloran S, et al. Probiotic impact on microbial flora inflammation and tumor development in IL-10 knock out mice. Aliment Pharmacol Ther 2001; in press.
38. Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 1995; 3: 171-174.
39. Present DH. Ciprofloxacin as a treatment for ulcerative colitis - not yet. Gastroenterology 1998, 115: 1289-1291.
40. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405.
41. Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta 2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945-953.
42. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon ATR. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-639.
43. Rook GAW, Stanford JL. Give us this day our daily germs. Immunol Today 1998; 19: 113-116.
44. Rutgeert P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-963.
45. Rutgeerts P, Geboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338: 771-774.
46. Sartor RB. Enteric microflora in IBD: pathogens or commensals? Inflamm Bowel Dis 1997; 3: 230-235.
47. Sartor RB. Postoperative recurrence of Crohn's disease: the enemy is within the fecal stream. Gastroenterology 1998; 114: 398-407.
48. Shanahan F. The intestinal immune system. In: Johnson LR, Alpers D, Christensen J, Jacobson E, Walsh JH. eds. Physiology of the gastrointestinal tract. 3rd ed. New York: Raven Press. 1994; 643-684.
49. Shanahan F. Mechanisms of immunologic sensation of intestinal contents. Am J Physiol. Gastrointest Liver Physiol 2000; 278: G191-G196.
50. Shanahan F. Immunologic and genetic Links in Crohn's disease. Gut 2000; 46: 6-7.
51. Shanahan F. Therapeutic manipulation of gut flora. Science 2000; 289: 1311-1312.
52. Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm Bowel Dis 2000; 6: 107-115.
53. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics and ecotherapeutics. Gastroenterology 2001; 120: 622-635.
54. Steidler I, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289: 1352-1355.
55. Sutton CL, Kim J, Yamane A, et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 2000; 119: 23-31.
56. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997; 337: 1029-1035.
57. Tytgat GNJ, Mulder CJJ, Brummelkamp WH. Endoscopic lesions in Crohn's disease early after ileocecal resection. Endoscopy 1988; 20: 260-262.
58. Van de Merwe JP, Stegeman JH, Hazenberg MP. The resident faecal flora is determined by genetic characteristics of the host. Implications for Crohn's disease? Antonie van Leeuwenhoek 1983; 49: 119-124.
59. Walmsley RS, Anthony A, Sim R, Pounder RE, Wakefield AJ. Absence of Esherichia coli, Listeria monocytogenes, and Klebsiella pneumoniae antigens within inflammatory bowel disease tissues. J Clin Pathol 1998; 51: 657-661.